Association of TGF-beta1 gene polymorphisms in exon1 and blood levels with essential hypertension

Association between potassium channel SNPs and essential hypertension in Xinjiang Kazak Chinese patients

The aim of the present study was to examine whether single-nucleotide polymorphisms (SNPs) of β1 subunit of large-conductance Ca²⁺-activated K⁺ channel (KCNMB1) and inwardly rectifying K⁺ channel, subfamily J, member-11 (KCNJ11) are associated with essential hypertension (EH) in Xinjiang Kazak Chinese patients. A polymerase chain reaction-restriction fragment length polymorphism technique was applied to detect the distribution of selected alleles and genotype frequencies in a cohort of Xinjiang Kazak Chinese patients. Samples from 267 patients with EH and 259 normotensive (NT) controls were analyzed. An unconditional logistic regression analysis was used to estimate the odds ratio and 95% confidence interval of the risk factors that are associated with the development of EH. Genotype and allele frequency analyses revealed that the frequency of genotypes KCNJ11-rs2285676 and KCNMB1-rs11739136 was not significantly different between the EH and NT groups. Individuals carrying the GG genotype of KCNJ11-rs5219 had a 2.08 times higher risk of having EH than individuals carrying the GA+AA genotype of KCNJ11-rs5219. Furthermore, the G allele frequency of KCNJ11-rs5219 in the EH group was significantly higher than that of the NT group (P=0.048). Additionally, logistic regression analysis revealed that the body weight and GG genotype of KCNJ11-rs5219 were positively associated with EH in Xinjiang Kazak Chinese patients (P<0.01).

Elastin microfibril interface-located protein 1, transforming growth factor beta, and implications on cardiovascular complications

Elastin microfibril interface-located protein 1 (EMILIN1), a glycoprotein, is associated with elastin in the extracellular matrix (ECM) of arteries, lymph vasculature, and other tissues. EMILIN1 particularly has a niche role in elastin fiber biogenesis (elastogenesis) by aiding with the fusion of elastin fibers, rendering them more ordered. In addition to elastogenesis, EMILIN1 has been shown to have roles in maintenance of vascular cell morphology, smooth muscle cell adhesion to elastic fibers, and transforming growth factor (TGFβ) regulation, by inhibiting TGFβ activation via blocking the proteolytic production of the latency-associated peptide/active TGFβ complex. The increased TGFβ signaling induced during EMILIN1 deficiency alters TGFβ activity, resulting in vascular smooth muscle cell growth and vascular remodeling. The increasing systemic blood pressure associated with TGFβ signaling may be closely linked to the activity of other mediators that affect cardiovascular homeostasis, such as angiotensin II. The increase in prevalence of hypertension and other cardiovascular diseases in other disease states likely involve a complex activation of TGFβ signaling and ECM dysfunction. Thus, the interaction of TGFβ and ECM components appears to be integrative involving both structural alterations to vessels through EMILIN1 and changes in TGFβ signaling processes. This review summarizes the current knowledge on the EMILIN1-TGFβ relationship; the specific roles of EMILIN1 and TGFβ in blood pressure regulation, their synergistic interaction, and in particular the role of TGFβ (in conjunction with ECM proteins) in other disease states altering cardiovascular homeostasis.

Frequency of TGF- β and IFN- γ genotype as risk factors for acute kidney injury and death in intensive care unit patients

Genetic variations in TGF-β and IFN-γ may interfere with proinflammatory cytokine production and, consequently, may be involved with inflammatory diseases, as acute kidney injury (AKI). We considered that genetic polymorphisms of these cytokines may have a crucial role in the outcome of critically ill patients. To investigate whether the genetic polymorphisms of rs1800470 (codon 10 T/C), rs1800471 (codon 25 C/G) from the TGF-β, and rs2430561 (+874 T/A) from IFN-γ may be a risk factor for ICU patients to the development of AKI and/or death. In a prospective nested case-control study, were included 139 ICU patients who developed AKI, 164 ICU patients without AKI, and 244 healthy individuals. We observed a higher frequency to T/A genotype for IFN-γ (intermediate producer phenotype) and higher frequency of TT GG and TC GG genotype (high producer) for TGF-β polymorphism in overall population. However, these polymorphisms have not been shown as a predictor of risk for AKI and death. We found an increased prevalence of high and intermediate producer phenotypes from TGF-β and IFN-γ, respectively, in patients in ICU setting. However, the studied genetic polymorphism of the TGF-β and IFN-γ was not associated as a risk factor for AKI or death in our population.

Polymorphisms and plasma level of transforming growth factor-Beta 1 and risk for preeclampsia: a systematic review

BACKGROUND

Transforming growth factor-beta 1 (TGF-β1) is thought to be involved in the pathogenesis of preeclampsia (PE), but the results are inconsistent among studies. This article aims to compile an overview of the studies about the associations of TGF-β 1 polymorphism and plasma level with PE risk and to provide recommendations for future research.

METHODS AND RESULTS

The databases PubMed, Embase and Web of Science were searched up to December 2013. Five studies investigating the associations of four polymorphisms with the risks of PE were involved. A meta-analysis was conducted for the 869T>C polymorphism and PE risk. The results show that genotype TT of 869T>C polymorphism is a protective factor of PE (pooled odds ratio=0.73, 95% CI: 0.56, 0.95). Eight case-control studies reported the plasma level of TGF-β 1. The substantial heterogeneity among studies may be attributed to the differences in the blood sample processing and the TGF-β 1 analysis kits. The results suggest that plasma TGF-β 1 level in the second trimester was significantly lower in the PE group than in the normal pregnancy group, but was significantly higher in the PE group during the third trimester.

CONCLUSIONS

The current results support that the TGF-β 1 869 T>C polymorphism was associated with the risk of PE. However, the number of eligible studies is small and more studies are needed to clarify whether this association can be detected on larger sample sizes and different populations. Owing to the heterogeneity between studies, no conclusion on the association between plasma TGF-β 1 level and PE risk can be drawn from this review. Further studies about the TGF-β 1 levels at different stages of pregnancy and the development of TGF-β 1 assay methodology are required to reveal the role of TGF-β 1 in the pathological development of PE.

Between candidate genes and whole genomes: time for alternative approaches in blood pressure genetics

Blood pressure has a significant genetic component, but less than 3% of the observed variance has been attributed to genetic variants identified to date. Candidate gene studies of rare, monogenic hypertensive syndromes have conclusively implicated several genes altering renal sodium balance, and studies of essential hypertension have inconsistently implicated over 50 genes in pathways affecting renal sodium balance and other functions. Genome-wide linkage scans have replicated numerous quantitative trait loci throughout the genome, and over 50 single nucleotide polymorphisms (SNPs) have been replicated in multiple genome-wide association studies. These studies provide considerable evidence that epistasis and other interactions play a role in the genetic architecture of blood pressure regulation, but candidate gene studies have limited scope to test for epistasis, and genome-wide studies have low power for both main effects and interactions. This review summarizes the genetic findings to date for blood pressure, and it proposes focused, pathway-based approaches involving epistasis, gene-environment interactions, and next-generation sequencing to further the genetic dissection of blood pressure and hypertension.

Transforming growth factor-β1 gene +869T/C, but not +915G/C polymorphism is associated with essential hypertension in a Chinese patient cohort

Many studies have suggested that transforming growth factor-β1 (TGF-β1) gene might be involved in the development of hypertension. However, results have been inconsistent. In this study, the authors performed a meta-analysis to investigate the associations of +869T/C and +915G/C polymorphisms in TGF-β1 gene with hypertension risk in Chinese. Published literature from PubMed, EMBASE, CNKI, CBM, and Wanfang Data were searched. Pooled odds ratio (OR) and 95% confidence interval (CI) were calculated using fixed or random-effects model. Nine studies (1,995 cases/1,840 controls) for +869T/C polymorphism and seven studies (1,547 cases/1,577 controls) for +915G/C polymorphism were included in the meta-analysis. The overall result showed that there was a statistically significant association between +869T/C polymorphism and hypertension risk (CC vs. TT: OR = 1.80, 95% CI 1.34-2.44). Similar results were found among two geographic locations and two subgroups with different sample size. However, no significant association was found for +915G/C polymorphism with the risk of hypertension (CC vs. GG: OR = 1.66, 95% CI 0.74-3.74). The meta-analysis indicated the significant association of +869T/C, but not +915G/C polymorphism with hypertension susceptibility. However, given the limited sample size, the associations warrant further investigation.

Transforming growth factor-β and atherosclerosis: interwoven atherogenic and atheroprotective aspects

Age-related progression of cardiovascular disease is by far the largest health problem in the US and involves vascular damage, progressive vascular fibrosis and the accumulation of lipid-rich atherosclerotic lesions. Advanced lesions can restrict flow to key organs and can trigger occlusive thrombosis resulting in a stroke or myocardial infarction. Transforming growth factor-beta (TGF-β) is a major orchestrator of the fibroproliferative response to tissue damage. In the early stages of repair, TGF-β is released from platelets and activated from matrix reservoirs; it then stimulates the chemotaxis of repair cells, modulates immunity and inflammation and induces matrix production. At later stages, it negatively regulates fibrosis through its strong antiproliferative and apoptotic effects on fibrotic cells. In advanced lesions, TGF-β might be important in arterial calcification, commonly referred to as "hardening of the arteries". Because TGF-β can signal through multiple pathways, namely the SMADs, a MAPK pathway and the Rho/ROCK pathways, selective defects in TGF-β signaling can disrupt otherwise coordinated pathways of tissue regeneration. TGF-β is known to control cell proliferation, cell migration, matrix synthesis, wound contraction, calcification and the immune response, all being major components of the atherosclerotic process. However, many of the effects of TGF-β are essential to normal tissue repair and thus, TGF-β is often thought to be "atheroprotective". The present review attempts to parse systematically the known effects of TGF-β on both the major risk factors for atherosclerosis and to isolate the role of TGF-β in the many component pathways involved in atherogenesis.

Association of 29C>T polymorphism in the transforming growth factor-β1 gene with lean body mass in community-dwelling Japanese population

AIM

Sarcopenia is the significant degenerative loss of skeletal muscle mass and strength associated with aging, and it is one of the components of frailty. We previously reported an association between the 29C>T polymorphism in the transforming growth factor-β1 gene (rs1800470) and the prevalence of vertebral fractures in subjects with postmenopausal osteoporosis. The association was not attributable to bone mineral density, which suggests that polymorphism influences some aspects of bone quality that affects strength and/or frailty rather than bone strength itself. Thus, we examined the relationship between genetic polymorphism and lean body mass in a Japanese population.

METHODS

A total of 479 adults comprising 143 men and 336 women, age 23 to 85 years, participated in the present study. Fat-free mass was measured by dual energy X-ray absorptiometry, and the relative skeletal muscle index was calculated as the ratio of appendicular (sum of arms and legs) fat-free mass to the square of height.

RESULTS

Total, leg, and appendicular fat-free mass as well as the relative skeletal muscle index were significantly lower in male subjects with CT/TT genotypes compared to those with CC genotype. Female subjects did not show any genotype-dependent differences when analyzed as a group, but when those without menstruation (postmenopausal women) were analyzed, arm fat-free mass was significantly lower in the CT/TT genotypes than in the CC genotype.

CONCLUSIONS

T allele of the 29C>T polymorphism in the transforming growth factor-β1 gene might be a risk factor of sarcopenia in a Japanese population.

Evaluation of Transforming Growth Factor Beta-1 Gene 869T/C Polymorphism with Hypertension: A Meta-Analysis

Association between transforming growth factor beta-1 gene (TGFB1) 869T/C polymorphism and hypertension has been widely evaluated, yet with conflicting results. As meta-analysis is a reliable way to resolve discrepancies; I aimed to evaluate this association. Data were available from 9 study populations involving 6151 subjects. Overall, comparison of allele 869C with 869T generated a significant 30% increased hypertension risk (95% confidence interval [95% CI]: 1.11–1.51; P = 0.001), which was strengthened for homozygous comparison (869CC versus 869TT) with odds ratio (OR) doubled to 1.62 (95% CI: 1.23–2.14; P = 0.001). Stratified analysis by study design demonstrated stronger associations in population-based studies than in hospital-based studies with OR, except in the dominant model, being increased by 7.94–18.61%. Likewise, ethnicity-based analysis exhibited a contradictory association between Asians and Whites. Conclusively, these findings support the notion that TGFB1 gene 869T/C polymorphism may influence the risk of hypertension, especially in Asian populations.

Transforming growth factor β1 +869T/C gene polymorphism and essential hypertension: a meta-analysis involving 2708 participants in the Chinese population

BACKGROUND

The transforming growth factor β1 (TGFB1) +869T/C gene polymorphism has been suggested to be linked to susceptibility to essential hypertension (EH).

OBJECTIVE AND METHODS

To investigate the relationship between TGFB1 +869T/C gene polymorphism and EH, 5 separate studies with 2,708 subjects in the Chinese population on the relation between TGFB1 +869T/C gene polymorphism and EH were analyzed by meta-analysis. The random effect model was selected to calculate the pooled odds ratio (ORs) and its corresponding 95% confidence interval (95%).

RESULTS

There was a significant association between TGFB1 +869T/C gene polymorphism and EH. The pooled OR for CC/TC+TT genotype was 2.50 (95% CI: 1.46-4.28, P (heterogeneity) <0.0001, p=0.0008). The pooled OR for the frequency of C allele was 1.43 (95% CI:1.18-1.73, P (heterogeneity) =0.02, p=0.0002).

CONCLUSION

The current meta-analysis suggested that C allele and CC genotype of TGFB1 +869T/C gene polymorphism might be related to the increased risk of EH in the Chinese population.